July 19, 2022

Epeleuton receives orphan-drug designation for Sickle Cell Disease from the FDA

Dublin, Ireland, 19 July 2022: Afimmune, a privately held, clinical stage biopharmaceutical company, today announced that the Food and Drug Administration (FDA) in the United States […]
June 10, 2022

Data Showing Epeleuton As A Potential Treatment For Sickle Cell Disease Will Be Presented At The EHA 2022 Congress

Dublin, Ireland, 10 June 2022: Afimmune, a privately held, clinical stage biopharmaceutical company, today announced that results of its investigational drug Epeleuton will be presented at […]
August 26, 2021

Afimmune’s Epeleuton shows large decreases in viral load and pathological changes in COVID-19 study

Epeleuton decreases viral titres and SARS-CoV-2 RNA and histopathological damage in the upper and lower respiratory tract Dublin, Ireland, 26th August 2021 – Afimmune, a clinical stage drug discovery […]